Calamos Wealth Management LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 82,508 shares of the company’s stock after buying an additional 6,547 shares during the quarter. Johnson & Johnson accounts for approximately 1.5% of Calamos Wealth Management LLC’s portfolio, making the stock its 12th largest holding. Calamos Wealth Management LLC’s holdings in Johnson & Johnson were worth $10,727,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. OLD Point Trust & Financial Services N A grew its stake in shares of Johnson & Johnson by 2.2% in the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after purchasing an additional 1,321 shares during the last quarter. Welch & Forbes LLC lifted its holdings in Johnson & Johnson by 0.9% in the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after buying an additional 6,730 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Johnson & Johnson by 0.5% in the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after buying an additional 3,533 shares during the period. Oliver Luxxe Assets LLC lifted its holdings in Johnson & Johnson by 12.7% in the second quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock worth $2,320,000 after buying an additional 1,972 shares during the period. Finally, Sitrin Capital Management LLC lifted its holdings in Johnson & Johnson by 1.6% in the second quarter. Sitrin Capital Management LLC now owns 48,986 shares of the company’s stock worth $6,480,000 after buying an additional 792 shares during the period. 65.79% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson (NYSE JNJ) opened at $143.68 on Tuesday. Johnson & Johnson has a 1-year low of $112.43 and a 1-year high of $148.32. The firm has a market cap of $386,000.00, a P/E ratio of 368.41, a P/E/G ratio of 2.60 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The company had revenue of $20.20 billion during the quarter, compared to analyst estimates of $20.08 billion. During the same period in the previous year, the business earned $1.58 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.34%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 861.54%.

JNJ has been the subject of several research analyst reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Finally, Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $145.00 to $157.00 in a report on Wednesday, October 11th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $146.16.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/30/johnson-johnson-jnj-shares-bought-by-calamos-wealth-management-llc-updated-updated-updated.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.